Phase 1 Parkinson's Disease Trial, By Invitation NCT06344026 Sponsor: Aspen Neuroscience Condition: Parkinson's Disease
Back to Parkinsons Disease

Phase 1 Parkinson's Disease Trial, By Invitation

NCT06344026
By Invitation Phase 1

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who are between 40 and 75 years old at the time they agreed to take part in a related study called ANPD001-01.
  • People who met all the requirements to be included in that related study (ANPD001-01).
  • People who were diagnosed with Parkinson's disease at least 4 years ago.
  • People whose movement symptoms clearly improve when they take Levodopa (a common Parkinson's medication).

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have had previous brain surgery that a neurologist or neurosurgeon believes would make the treatment in this trial unsafe.
  • People who have previously had any brain-based treatment for Parkinson's disease, such as deep brain stimulation, focused ultrasound, gene therapy, or other biological treatments.
  • People with a history of significant memory or thinking problems, or dementia.
  • People with a history of a significant condition called Dopa Dysregulation Syndrome (an unhealthy relationship with Parkinson's medications) (confirm with trial site).
  • People with a history of epilepsy, stroke, multiple sclerosis, a poorly controlled or worsening neurological condition (other than Parkinson's), or poorly controlled heart or blood vessel disease.
  • People who are unable to temporarily stop taking blood-thinning or anti-clotting medications for at least 2 weeks.
  • People who have had a cancer diagnosis (in the brain or elsewhere in the body) within the past 5 years, except for certain treated skin cancers.
  • People for whom an MRI scan or the use of contrast dyes used in certain scans is not safe or suitable.
  • People who weigh more than 300 pounds or have a Body Mass Index (BMI) above 35.
  • People with newly diagnosed or poorly controlled diabetes, or any other serious ongoing or sudden health condition that would significantly raise the risks of brain surgery.
  • People who are pregnant or breastfeeding.
  • People who have significant uncontrolled movement side effects from their Parkinson's medication, based on a specific movement assessment scale.
  • People who are capable of having children but are unwilling to use barrier contraception (such as condoms) for 3 months after receiving the trial treatment.
  • People who are unable to follow the trial's procedures, including attending frequent and lengthy follow-up appointments.
  • People about whom a neurologist or neurosurgeon has raised any significant concern.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
By Invitation
Phase
Phase 1
Sponsor
Aspen Neuroscience
Registry
ClinicalTrials.gov
Start date
23 January 2024
Est. completion
30 March 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence and severity of treatment emergent adverse events (Safety and Tolerability)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov